Our findings are clinically impactful as there are already several FDA-approved, commercially available, anti-IL-23 monoclonal antibody therapies such as Ustekinumab, Risankizumab, and Guselkumab for treatment of psoriasis and other inflammatory conditions, which could be repurposed for NASH/NAFLD30–32. Here, IL37 is linked to psoriasis.